Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
US Eylea Biosimilar Approvals Set Up Competition On Aflibercept
Both Biocon And Biogen Receive Interchangeability Designations For Ophthalmic Treatment
May 21 2024
•
By
David Wallace
Biocon and Biogen have US approvals for aflibercept • Source: Shutterstock
More from Biosimilars
More from Products
